Psychiatry Research
Volume 169, Issue 2 , Pages 132-138 , 30 September 2009

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder

  • Andrew F. Leuchter

      Affiliations

    • Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, United States
    • Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    • Corresponding Author InformationCorresponding author. Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, Rm. 37-452, Los Angeles, CA 90024-1759, USA. Tel.: +1 310 825 0207; fax: +1 310 825 7642.
    • ,
  • Ian A. Cook

      Affiliations

    • Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, United States
    • Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    • ,
  • William S. Gilmer

      Affiliations

    • Department of Psychiatry, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
    • ,
  • Lauren B. Marangell

      Affiliations

    • Department of Psychiatry, Baylor College of Medicine, Houston, TX, United States
    • ,
  • Karl S. Burgoyne

      Affiliations

    • Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    • Department of Psychiatry, Harbor-UCLA Medical Center, Los Angeles, CA, United States
    • ,
  • Robert H. Howland

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA, United States
    • ,
  • Madhukar H. Trivedi

      Affiliations

    • Department of Psychiatry, University of Texas Southwestern Medical School, Dallas, TX, United States
    • ,
  • Sidney Zisook

      Affiliations

    • Department of Psychiatry, UCSD, San Diego, CA, United States
    • ,
  • Rakesh Jain

      Affiliations

    • Psychiatry, RD Clinical Research, Houston, TX, United States
    • ,
  • Maurizio Fava

      Affiliations

    • Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • ,
  • Dan Iosifescu

      Affiliations

    • Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
    • ,
  • Scott Greenwald

      Affiliations

    • Neuroscience, Aspect Medical Systems, Norwood, MA, United States

Received 16 January 2009 ,Revised 2 April 2009 ,Accepted 15 April 2009.

References 

  1. American Psychiatric Association . Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Washington, DC: APA; 2000;
  2. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World Journal of Biological Psychiatry. 2007;8(2):67–104
  3. Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opinion on Pharmacotherapy. 2007;8(4):457–466
  4. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal. 1995;310(6977):452–454
  5. Crowell SE, Beauchaine TP, Gatzke-Kopp L, Sylvers P, Mead H, Chipman-Chacon J. Autonomic correlates of attention-deficit/hyperactivity disorder and oppositional defiant disorder in preschool children. Journal of Abnormal Psychology. 2006;115(1):174–178
  6. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 1960;23:56–62
  7. Leuchter A, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depression Disorder. Journal of Psychiatric Practice. 2008;14(5):271–280
  8. Leuchter, A.F., Cook, I.A., Marangell, L.B., Gilmer, W.S., Burgoyne, K.S., Howland, R.H., Trivedi, M.H., Zisook, S., Jain, R., McCracken, J.T., Fava, M., Iosifescu, D., Greenwald, S., 2009. Effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI Treatment in major depressive disorder: results of BRITE-MD study of the BRITE-MD study. Psychiatry Research 169 (2).
  9. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry. 2007;62(11):1217–1227
  10. Rush AJ. Limitations in efficacy of antidepressant monotherapy. Journal of Clinical Psychiatry. 2007;68(Suppl 10):8–10
  11. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychological Medicine. 1996;26(3):477–486
  12. Rush AJ, Kupfer DJ. Strategies and tactics in the treatment of depression. In:  Gabbard GO editors. Treatments of Psychiatric Disorders. 3rd ed.. Washington, DC: American Psychiatric Press; 2001;
  13. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry. 2003;54(5):573–583
  14. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. Sequenced treatment alternatives to relieve depression (STAR⁎D): rationale and design. Controlled Clinical Trials. 2004;25(1):119–142
  15. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine. 2006;354(12):1231–1242
  16. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry. 1998;59(Suppl 20):22–33quiz 34–57
  17. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. Journal of Clinical Epidemiology. 2001;54(3):253–262
  18. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. Journal of Clinical Psychiatry. 2003;64(Suppl 13):13–17
  19. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry. 1997;58(Suppl 13):23–29
  20. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. Journal of Clinical Psychiatry. 1997;58(1):16–21
  21. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine. 2006;354:1243–1252
  22. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR⁎D: implications for clinical practice. American Journal of Psychiatry. 2006;163(1):28–40
  23. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA for the STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice. 2006;12(2):71–79
  24. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biological Psychiatry. 2006;59(3):203–210

PII: S0165-1781(09)00159-0

doi: 10.1016/j.psychres.2009.04.004

Psychiatry Research
Volume 169, Issue 2 , Pages 132-138 , 30 September 2009

Article Tools

* Image Usage & Resolution